depression
DEPRESSION

Depression is a mood disorder wherein the patient have a pervasive sad mood or loss of interest in most activities for at least 2 weeks.

It can cause significant distress & impairment. It is also a chronic, episodic and relapsing syndrome.

Treatment can either be by psychotherapy alone or pharmacotherapy alone or psychotherapy combined with pharmacological therapy.

Introduction

  • Patients may not present with depressive mood; somatic complaints may predominate
  • Depression should be suspected in patients who present with physical symptoms (eg fatigue, gastrointestinal distress or back pain) which cannot be explained or in those who present with pain, anxiety or substance abuse
  • Presence of depressed mood or diminished interest or pleasure in activities (anhedonia), feeling of fatigue or lack of energy (anergia), significant loss of motivation (avolition) are essential in diagnosing depression
  • Diagnosis may be easier in patients who are more aware of their moods or functioning
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 6 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 3 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Yesterday
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.